Modified Fc gamma receptor type III (FCγIII, HNA-1) polypeptides and the uses thereof
US10571468B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 7, 2015 |
| Grant date | Feb 25, 2020 |
| Priority date | — |
| Expiry date | Apr 19, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/245
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention is directed to engineered Fc gamma receptor type III (Fcγ111, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.